Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Stenocare ASFRA:S7C 40 Buyback Yield % is 0.00 as of Jul. 18, 2026. GuruFocus rates FRA:S7C with a GF Score™ of 40/100 and a GF Value™ of €0.29 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 291 Drug Manufacturers companies, Stenocare AS ranks worse than 343642.27% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Stenocare AS's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:S7C vs ZTS, UTHR, VTRS: Buyback Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Stenocare AS's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stenocare AS Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Stenocare AS's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Stenocare AS's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stenocare AS (FRA:S7C) has a Buyback Yield % of 0.00 as of Jul. 18, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Stenocare AS and its competitors. According to the industry distribution chart, Stenocare AS ranks #999999 out of 291 companies in the Drug Manufacturers industry.
Is Stenocare AS's Buyback Yield % too high?
Stenocare AS's current Buyback Yield % is 0.00. Based on the distribution chart, Stenocare AS ranks #999999 out of 291 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Stenocare AS has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Stenocare AS's Buyback Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Stenocare AS ranks #999999 out of 291 companies for Buyback Yield %. This places Stenocare AS in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Stenocare AS and its competitors. Stenocare AS's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stenocare AS stock overvalued right now?
Based on GuruFocus' analysis, Stenocare AS (FRA:S7C) is currently considered Possible Value Trap. The stock's GF Value™ is €0.29, compared to a current price of €0.13 — trading 56.2% below its estimated fair value. The current Buyback Yield % is 0.00. Stenocare AS's overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Stenocare AS (FRA:S7C), the current Buyback Yield % is 0.00 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stenocare AS (FRA:S7C) Overvalued in 2026?
Based on GuruFocus' analysis, Stenocare AS stock appears to be undervalued.
The current stock price of €0.13 is trading 56.2% below its estimated GF Value™ of €0.29.
GuruFocus considers Stenocare AS to be Possible Value Trap.
Key valuation signals for FRA:S7C:
Buyback Yield %: 0.00
GF Value™: €0.29 vs. price of €0.13 (56.2% below fair value)
No single metric tells the full story. See the FRA:S7C stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stenocare AS is a Danish company engaged in the cultivation and production of medical cannabis products through pharmacies and hospitals. The company's business operations include the distribution and sales of imported products to several markets which also includes local cultivation and production of its medical cannabis products. Stenocare is well positioned to become a market leader in Denmark and a vendor in Europe. The company is a supplier of medical cannabis oil for patients in Denmerk, Sweden, UK, Australia and Norway.
40GF Score
Get the complete analysis for FRA:S7C
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:S7C has been successfully added to your 
